---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-099900"
form_type: "8-K"
ticker: "BTAI"
cik: "0001720893"
company_name: "BioXcel Therapeutics, Inc."
filed_at: "2026-08-24T11:00:28+00:00"
generated_at: "2026-08-24T11:05:44.055599+00:00"
event_type: "debt"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# BioXcel extends debt repayment deadline to Aug 28, 2026 via Thirteenth Amendment

## Summary
- Thirteenth Amendment dated Aug 21, 2026 extends deadline from Aug 21 to Aug 28, 2026 for definitive agreements.
- Company must enter transactions for full repayment of all obligations or alternative capital solutions acceptable to lenders.
- Obligors must consider lender comments on regulatory processes involving material assets through Aug 28, 2026.
- All other Credit Agreement terms remain in effect; no waiver of lender rights or remedies.

## SEC filing metadata
- accession: 0001104659-26-099900
- form_type: 8-K
- ticker: BTAI
- cik: 0001720893
- company_name: BioXcel Therapeutics, Inc.
- filed_at: 2026-08-24T11:00:28+00:00
- event_type: debt
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1720893/000110465926099900/0001104659-26-099900-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1720893/000110465926099900/tm2623861d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-099900
- JSON: https://secwatch.observer/filing/0001104659-26-099900.json
- Plain text: https://secwatch.observer/filing/0001104659-26-099900.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.